A new class of medicines has done what a generation of diet books could not: it has made a large group of people less hungry. GLP-1 drugs, first developed for diabetes and now used for weight loss, are changing supermarket baskets, restaurant portions and the meaning of “willpower”.
They are also exposing a hole in the NHS. Patients can lose weight at speed while eating far too little protein, fibre and micronutrients. Muscle loss is a real risk, especially in older adults. Yet dietetic follow-up is patchy, and private prescriptions often come with little more than an app and a weekly weigh-in.
“These drugs are a tool, not a diet,” said Dr Helen Cartwright, Nutrition Editor of this paper. “If you silence appetite and then live on cheese sandwiches and tea, you will get a smaller body and a worse nutritional state.”
NICE has narrowed NHS access to the most clinically eligible patients. The private market has not. Pharmacies, online clinics and celebrity before-and-afters have turned a specialist treatment into a cultural event. Food companies are already reformulating: higher-protein snacks, smaller premium portions, “GLP-1 friendly” ranges that may or may not deserve the name.
Public health officials are split. Some see a chance to cut obesity-related disease at last. Others worry that a medical fix will let the food environment off the hook, and that those who cannot pay will be left with the same cheap calories as before.
The next year will test whether Britain can treat these drugs as part of nutrition policy rather than a fashion. That means protein and strength training alongside the pen, honest labelling of the new snack aisle, and an NHS pathway that does not end when the prescription is issued.